Share
    NEW SEARCH RETURN TO SEARCH RESULTS
Number: 201204076 Principal Investigator: Linette, Gerald
Title: An Open-Label, Multicenter, Phase II Study of Continuous Oral Vemurafenib in Patients with Locally Advanced, Unresectable, Stage IIIC or Metastatic Melanoma and Activating Exon 15 BRAF Mutations other than V600E
Phase: II Disease Site: Melanoma, Skin
Participating Site(s):
 
Main Campus
Map and Directions
 
Contact: 800-600-3606 or info@ccadmin.wustl.edu

Description:
The purpose of this study is to assess the potential side effects and effectiveness of vemurafenib as an investigational drug for the treatment of metastatic melanoma in patients with other than BRAF V600E mutations.
 
More Information:
ClinicalTrials.gov Link
Internal Protocol Documents (requires Siteman administrative database password)